Drug Trial News

RSS

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

26 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

Better drug design may soon be aided by Scripps scientists’ discoveries

For the first time, they have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output. These new findings could aid future drug design by giving scientists an edge in fine tuning the signal between these partnered proteins—and the drug’s course of action.

25 Aug 2015

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

Cancer researchers are constantly in search of more-effective and less-toxic approaches to stopping the disease, and have recently launched clinical trials testing a new class of drugs called BET inhibitors. These therapies act on a group of proteins that help regulate the expression of many genes, some of which play a role in cancer.

25 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.

23 Aug 2015

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

Kessler researchers found preliminary evidence for the effectiveness of ramelteon for the treatment of sleep disturbances after traumatic brain injury (TBI). The article, "Archives of Physical Medicine and Rehabilitation on May 28, 2015. Authors are Anthony Lequerica, PhD, and Nancy Chiaravalloti, PhD, of Kessler Foundation, Neil Jasey, MD, of Kessler Institute for Rehabilitation, and Jaclyn Portelli Tremont, MA, of Robert Wood Johnson Medical School, Rutgers University.

21 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.

20 Aug 2015

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events.

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

H1N1 vaccine developed at UNMC to be evaluated in animal study

An H1N1 vaccine developed at the University of Nebraska Medical Center will enter a definitive round of testing this month, and researchers hope to establish its ability to ward off the virus.

20 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Oncolytic virotherapy lends benefits to melanoma patients

Recent study published online by Melanoma Research journal indicates that melanoma patients would significantly benefit from prolonging the survival with oncolytic viroherapy treatment. The study revealed that the early stage melanoma patients treated with oncolytic medicine Rigvir were 4 to 6 times more likely to survive than those who following the current guidelines for the treatment of melanoma were only observed.

19 Aug 2015

Common diabetes drug metformin works in gut, not the bloodstream

Although metformin was introduced as a treatment for type 2 diabetes nearly 60 years ago and is now the recommended first-line treatment for newly diagnosed patients, researchers still debate precisely how the drug works.

19 Aug 2015

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

TapImmune announces successful conveyance of Investigational New Drug Application from Mayo Clinic

TapImmune, Inc., a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application) to TapImmune as part of the recently completed licensing agreement.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Drug Trial News

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

Better drug design may soon be aided by Scripps scientists’ discoveries

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

60P to commence Phase II clinical trial among dengue fever patients

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

H1N1 vaccine developed at UNMC to be evaluated in animal study

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

Oncolytic virotherapy lends benefits to melanoma patients

Common diabetes drug metformin works in gut, not the bloodstream

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

TapImmune announces successful conveyance of Investigational New Drug Application from Mayo Clinic

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News